![2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole dihydrochloride structure, CAS 97657-92-6](/structures/210000/190532_1_97657_92_6.png)
CAS Number97657-92-6
SynonymsDimebolin; LATREPIRDINE DIHYDROCHLORIDE; dimebolin dihydrochloride; Latrepirdine; Latrepirdine,Dimebolin,Dimebon; Latrepirdine dihydrochloride (USAN); Dimebolin hydrochloride; Dimebon dihydrochloride; Dimebon,Latrepirdine; Latrepirdine (dihydrochloride)
Molecular FormulaC21H27Cl2N3
Molecular Weight392.37 (anhydrous basis)
Purity98.00%
Appearancewhite to off-white
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 97657-92-6 |
| Catalog No. | 2A-1189141 |
| Chinese Name | Latrepirdine dihydrochloride |
| Synonyms | Dimebolin; LATREPIRDINE DIHYDROCHLORIDE; dimebolin dihydrochloride; Latrepirdine; Latrepirdine,Dimebolin,Dimebon; Latrepirdine dihydrochloride (USAN); Dimebolin hydrochloride; Dimebon dihydrochloride; Dimebon,Latrepirdine; Latrepirdine (dihydrochloride) |
| Molecular Formula | C21H27Cl2N3 |
| Molecular Weight | 392.37 (anhydrous basis) |
| Purity | 98.00 |
| Appearance | white to off-white |
| Water Solubility | H2O: ≥10mg/mL |
| Storage Condition | Desiccate at RT |
| Application | Latrepirdine dihydrochloride is a neuroactive compound with antagonistic activity at histamine receptors, α-adrenergic receptors and serotonergic receptors. Latrepirdine stimulates amyloid precursor p |
| PubChem ID | 329798824 |
| MDL Number | MFCD17215933 |
| SMILES | Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1.Cl.Cl |
| InChI | InChI=1S/C21H25N3.2ClH/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17;;/h4-7,12-13H,8-11,14H2,1-3H3;2*1H |
| InChI Key | GTWLIQOLGOZTLF-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | transportation |
| Bioactivity | Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β (Aβ) secretion. Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Signaling Pathways >> Neuronal Signaling >> Amyloid-β Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> GPCR/G Protein >> Histamine Receptor Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Neurological Disease Target Amyloid-β (Aβ), Histaminergic receptor, α-adrenergic receptor, Serotonergic receptor[1] In Vitro Latrepirdine has been reported to possess several properties that are potentially relevant to the treatment of neurodegenerative diseases: (1) protection of cultured cells from the cytotoxicity of amyloid-β (Aβ) peptide; (2) stabilization of mitochondrial function and calcium homeostasis; (3) modulation of Aβ release from cultured cells, isolated intact nerve terminals, and from hippocampal neurons in living mouse brain; and (4) promotion of neurogenesis in the murine hippocampus. Treatment of cultured mammalian cells with Latrepirdine leads to enhanced mTOR- and Atg5-dependent autophagy. Latrepirdine modulates Atg5-dependent autophagic activity in a dose-dependent manner and via the mTOR-signaling pathway. HeLa cells stably expressing LC3 fused are treated with EGFP (eGFP-LC3) for 3 or 6 hours in the absence or presence of 50 μM Latrepirdine. Treatment with Latrepirdine for 3 or 6 hours markedly enhances the number of eGFP-LC3 punctae, indicating that Latrepirdine induces formation of autophagosomes. Next, mouse N2a neuroblastoma cells are treated in the absence (vehicle) or presence of 5 nM, 500 nM or 50 μM Latrepirdine for 3 or 6 hours in order to determine the effects of acute drug treatment on the regulation of autophagy. A significant and dose-dependent increase is observed in LC3-II levels in N2a cells following 3- or 6-hour treatment with either 500 nM or 50 μM Latrepirdine. A significant decrease of p-mTOR and p-S6K from N2a cells treated with 50 μM Latrepirdine for 3 hours is observed, whereas the total mTOR and p70S6K levels remain relatively constant[1]. In Vivo Latrepirdine treatment of TgCRND8 transgenic mice is associated with improved learning behavior and with a reduction in accumulation of Aβ42 and α-synuclein. Male, 90-day-old TgCRND8 mice or their wild-type littermates (nTg) receive 31 consecutive once daily i.p. injections of either 3.5 mg/kg Latrepirdine or 0.9% saline (vehicle). At the culmination of treatment, mice are tested for cued and contextual fear conditioning using a paradigm that has been widely accepted for evaluating learning and memory deficits in APP transgenic mice. A significant increase in cued memory only among Latrepirdine-versus vehicle-treated TgCRND8 mice (p=0.01) is observed. A weak, non-significant trend toward an improvement in contextual memory among Latrepirdine-versus vehicle-treated mice (p=0.099) is also observed[1]. Cell Assay N2a cells, stable human cervical carcinoma (HeLa) cells expressing EGFP-LC3, and mouse embryonic fibroblasts (MEFs) derived from wildtype mice or ATG5-/- mice are maintained in "growth medium" (high glucose Dulbecco's modified Eagle's medium supplemented with 10% FBS and 100 units/mL Penicillin/Streptomycin) at 37°C, 5% CO2. N2a cells stably transfected with APPK670N, M671L are maintained in growth medium supplemented with 0.2 mg/mL G418. Cells are washed 1× with ice cold PBS (pH 7.4) then incubated with either Latrepirdine (5 nM, 500 nM or 50 μM) or vehicle (growth medium). Following 3-, 6-, or 24-hour of treatment, cells are washed 1x with ice cold PBS, and collected in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM Pepstatin, 1 mM PMSF, 1% Triton X-100, EDTA-free mini-complete protease inhibitor cocktail tablet) then centrifuged (14,000 RPM) for 15 minutes at 4°C. For time-course experiments, cells are washed 2× with ice-cold PBS (pH 7.4) and incubated for the indicated time in serum-free DMEM containing 50 μg/mL CHX or 50 μg/mL Cycloheximide (CHX)+50 μg/mL Chloroquine (CQ). Baseline (T0) samples are collected immediately prior to treatment[1]. Animal Admin Mice[1] Male 53-55-day-old TgCRND8 mice (N=25) are randomly distributed into either of the two treatment groups: Latrepirdine (n=13 TgCRND8) or vehicle (n=12 TgCRND8). Animals receive 21 consecutive once daily intraperitoneal injections of either 3.5 mg/kg Latrepirdine or 0.9% saline (vehicle). 90-day-old male TgCRND8 mice (N=28) or their wild-type littermates (N=56) are randomly distributed into either of two treatment groups: Latrepirdine (n=13 TgCRND8; n=21 nTg) or vehicle (n=15 TgCRND8; n=25 nTg). Following treatment, animals are sacrificed and transcardially perfused with ice-cold PBS (pH 7.4). Male 90-day-old (n=5 per genotype) or 120-day-old (n=6 per genotype) TgCRND8 mice or their non-transgenic littermates are sacrificed and transcardially perfused with ice-cold PBS (pH 7.4). One hemisphere from each mouse is post-fixed in 4% paraformaldeyhde in PBS (pH 7.4) for histological analysis and the other hemisphere is dissected and snap-frozen for biochemical analysis. References [1]. Steele JW, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry. 2013 Aug;18(8):889-97. Chemical & Physical Properties Molecular Formula C21H27Cl2N3 Molecular Weight 392.365 Exact Mass 391.158203 PSA 21.06000 LogP 5.42560 Appearance of Characters white to off-white InChIKey GTWLIQOLGOZTLF-UHFFFAOYSA-N SMILES Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1.Cl.Cl Storage condition Desiccate at RT Water Solubility H2O: ≥10mg/mL |
| Use of | Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β (Aβ) secretion. Properties Name 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole,dihydrochloride Synonym More Synonyms Latrepirdine Biological Activity Description Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid-β (Aβ) secretion. Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Signaling Pathways >> Neuronal Signaling >> Amyloid-β Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> GPCR/G Protein >> Histamine Receptor Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Neurological Disease Amyloid-β (Aβ), Histaminergic receptor, α-adrenergic receptor, Serotonergic receptor[1] In Vitro Latrepirdine has been reported to possess several properties that are potentially relevant to the treatment of neurodegenerative diseases: (1) protection of cultured cells from the cytotoxicity of amyloid-β (Aβ) peptide; (2) stabilization of mitochondrial function and calcium homeostasis; (3) modulation of Aβ release from cultured cells, isolated intact nerve terminals, and from hippocampal neurons in living mouse brain; and (4) promotion of neurogenesis in the murine hippocampus. Treatment of cultured mammalian cells with Latrepirdine leads to enhanced mTOR- and Atg5-dependent autophagy. Latrepirdine modulates Atg5-dependent autophagic activity in a dose-dependent manner and via the mTOR-signaling pathway. HeLa cells stably expressing LC3 fused are treated with EGFP (eGFP-LC3) for 3 or 6 hours in the absence or presence of 50 μM Latrepirdine. Treatment with Latrepirdine for 3 or 6 hours markedly enhances the number of eGFP-LC3 punctae, indicating that Latrepirdine induces formation of autophagosomes. Next, mouse N2a neuroblastoma cells are treated in the absence (vehicle) or presence of 5 nM, 500 nM or 50 μM Latrepirdine for 3 or 6 hours in order to determine the effects of acute drug treatment on the regulation of autophagy. A significant and dose-dependent increase is observed in LC3-II levels in N2a cells following 3- or 6-hour treatment with either 500 nM or 50 μM Latrepirdine. A significant decrease of p-mTOR and p-S6K from N2a cells treated with 50 μM Latrepirdine for 3 hours is observed, whereas the total mTOR and p70S6K levels remain relatively constant[1]. References [1]. Steele JW, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry. 2013 Aug;18(8):889-97. Chemical & Physical Properties Exact Mass 391.158203 PSA 21.06000 LogP 5.42560 Appearance of Characters white to off-white InChIKey GTWLIQOLGOZTLF-UHFFFAOYSA-N Storage condition Desiccate at RT |
| Transport Info | Product name: Purity: 96.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Heterocyclic Building Blocks | ||
|---|---|---|
| 5H-Cyclopentapyrazine, 6,7-dihydro-2,5-dimethyl- | 38917-61-2 | 2A-1189076 |
| 4,6,6-TRIMETHYLBICYCLO[3.1.1]HEPT-3-EN-2-ONE | 80-57-9 | 2A-1189100 |
| 6-Methyl-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylic acid | 1249049-37-3 | 2A-1189106 |
| 1H-Isoindole-1,3(2H)-dione, 2-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]- | 88752-28-7 | 2A-1189134 |
| 2,4-PyriMidinediaMine, 5-[5-iodo-4-Methoxy-2-(1-Methylethyl)phenoxy]- | 865305-30-2 | 2A-1189135 |
| 1,3,5-Triazine,2,4-dichloro-6-(4-dibenzofuranyl)- | 51800-19-2 | 2A-2189165 |
| 2-(4-Bromophenyl)-4-phenylquinazoline | 540466-42-0 | 2A-2189169 |
| 1H-Benzimidazole, 1-(3-bromophenyl)-2-phenyl- | 1171247-63-4 | 2A-2189171 |
| 2-(4-bromophenyl)-4,6-di(naphthalen-2-yl)-1,3,5-triazine | 1616841-66-7 | 2A-2189172 |
| 2-(4-BroMophenyl)-4,6-diphenylpyridine | 3557-70-8 | 2A-2189175 |
| Browse all Heterocyclic Building Blocks products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS